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in Young Adults*
Michael A. Weber, MDSEE PAGE 327E pidemiologic studies show a strong relation-ship between blood pressure (BP) mea-surements and the incidence of major
cardiovascular events (1). The primary basis for the
treatment of hypertension has been the belief that
reducing BP provides cardiovascular protection. This
is supported by evidence from pivotal clinical trials
(2–7), conducted mostly in older patients at high car-
diovascular risk, because they experience sufﬁcient
events to power the analysis of outcomes. An unfor-
tunate consequence is the scarcity of data for
younger, less complex patients.
Even so, published guidelines on the management
of hypertension have tended to treat all adults ($18
years of age) alike, despite the probability of age-
dependent differences in outcomes. But 1 group of
U.S. experts recently recommended a higher BP
threshold for diagnosis and treatment of hyperten-
sion in adults $60 years of age than in younger adults
(8), and an expert opinion in another guideline rec-
ommended treating young adults to a lower BP than
recommended for middle-aged and older adults (9).
IMPORTANT NEW OBSERVATIONS
IN YOUNG ADULTS
In this issue of the Journal, Yano et al. (10) report a
study in which they used the database of the Chicago
Heart Association Detection Project in Industry, a
31-year longitudinal observation of cardiovascular
outcomes in young to middle-aged adults (11), to*Editorials published in the Journal of the American College of Cardiology
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paper to disclose.establish a relationship between baseline BP and
long-term cardiovascular outcomes, speciﬁcally car-
diovascular death and coronary heart disease (CHD)
death, in subgroups of individuals with normal BP
and with hypertension.This work focused on isolated systolic hyperten-
sion (ISH), deﬁned as systolic BP $140 mm Hg and
diastolic BP <90 mm Hg. Using a reference patient
group with optimal-normal BP (<130/85 mm Hg), the
investigators calculated hazard ratios for major events
in patients deﬁned as high-normal (130 to 139/85 to
89 mm Hg), ISH (deﬁned previously), isolated dia-
stolic hypertension (<140/$90 mm Hg), and systolic
diastolic hypertension ($140/90 mm Hg). In both
sexes, the risks for death from cardiovascular disease
and CHD in the high-normal and the ISH groups were
signiﬁcantly higher. Men, but not women, with iso-
lated diastolic hypertension also had a greater risk,
although relatively few patients had this condition.
Patients with combined systolic and diastolic hyper-
tension had the greatest incidence of events.
Whether these elevated BP category deﬁnitions
provide insights beyond simply establishing higher
than normal BP as a cardiovascular risk is uncertain.
For instance, systolic and diastolic BPs were both
clearly higher in patients with ISH compared with the
normal reference group. Furthermore, those with
systolic and diastolic hypertension had both higher
systolic and diastolic BPs than those with ISH. Thus, it
is difﬁcult to ascertain whether diastolic and systolic
BPs are independent major determinants of outcomes
and whether these various BP categories—on the basis
of the traditional 140/90 mm Hg threshold—provide
practical assistance.
Still, ISH in younger people has largely been un-
recognized, so this report resolves an important un-
certainty (10). Consistent with recommendations
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Epidemiology indicates a continuous relationship between blood pressure (BP) and event
rates. However, extrapolations from clinical trials reveal a more complex relationship
between BP and beneﬁts of treatment. There might be different targets for optimal event
reductions in patients $80 years of age (4), as well as for myocardial infarction (6,7),
kidney disease (6,18), cardiovascular death (6,7), and stroke (6,17) in adults <80 years of
age. Guidelines (9,12) recommend an overall systolic BP target of <140 mm Hg in
adults <80 years of age, but a lower target might be considered in young adults (despite a
lack of evidence from clinical trials).
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337from current clinical hypertension guidelines (8,9,12),
elevated systolic or diastolic BP or both should clearly
be considered abnormal in young adults and lead to
therapy.
CONFOUNDING FACTORS
ISH patients had a higher incidence of concomitant
risks than control patients, including a higher body
mass index, and higher likelihood of being smokers,
having abnormal lipid proﬁles, and having type 2
diabetes (10). However, when these factors were
incorporated into models for calculating hazard ratios
for major events, the cardiovascular event rate in the
ISH group was still signiﬁcantly higher.
It is not possible to account for every factor that
might inﬂuence these analyses, and so-called residual
confounding (as acknowledged by Yano et al. [10])
can include diet, alcohol intake, and psychological
characteristics. Important physiologic mediators
also inﬂuence hypertension outcomes. The renin-
angiotensin system plays an important mechanistic
role in raising BP as well as also increasing the risk for
cardiovascular outcomes. For instance, in a work-site
study of men with hypertension, those with high
renin levels had signiﬁcantly higher myocardial
infarction rates (13).
FURTHER CONSIDERATIONS IN THE YOUNG
BP has 2 separate roles in hypertension: 1) as a
biomarker of underlying vascular disease; and
2) accelerating the progress of vascular pathology and
precipitating clinical events. It is strongly believed
that vascular changes start in childhood and that early,
effective management may be critical in protecting
against later cardiovascular outcomes. Unfortunately,
a recent U.S. Preventive Services Task Force evalua-
tion of childhood hypertension concluded that,
without direct evidence linking control of childhood
hypertension to prevention of events in adults, it is not
possible to make recommendations for dealing with
BP abnormalities in children (14). This apparently
nihilistic opinion was strongly disputed by pediatric
hypertension experts (15). Given the ﬁnancial and lo-
gistic barriers to long-term outcomes studies origi-
nating in children and adolescents, developing a
strategy to provide direction in this area—even if it
depends on surrogate endpoints—is critical.
EPIDEMIOLOGY AND
CLINICAL TRIAL EVIDENCE
Experts in writing guidelines argue that recommen-
dations for managing hypertension must be drivenby clinical trial outcomes that deﬁne optimal BP
thresholds for diagnosis and treatment. Despite many
trials conducted in middle-aged and elderly patients
with hypertension, this type of evidence is limited.
The 2 trials that prospectively compared outcomes of
differing BP treatment targets resulted in only limited
data (16,17); thus, most knowledge depends on post-
hoc extrapolations from trials designed for other
purposes. The Systolic Hypertension in the Elderly
Program, a study of ISH (deﬁned as 160/90 mm Hg
rather than 140/90 mm Hg) in patients $60 years of
age, demonstrated a clear beneﬁt of active treatment
compared with placebo (2). Although this authorita-
tive trial strongly inﬂuenced contemporary guide-
lines (8,9,12), it was not designed to identify a BP
threshold. Post-hoc analyses from several trials have
led to the belief that certain levels of BP appear to be
associated with reductions in events (2–7,17). Figure 1
depicts BP targets associated with the best protection
against major outcomes and suggests that clinical
evidence does not fully correspond with epidemio-
logic data, particularly at the lower end of the BP
spectrum. Further prospective trials to guide clinical
practice are needed.
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338A NEED FOR ACTION
A lesson from the study of Yano et al. (10) is that even
in a young (mid-30s) cohort, systolic BP and CHD
death have a relationship resembling that in the
Prospective Studies Collaboration, in which systolic
BP increments of 20 mm Hg were associated with an
approximate doubling of CHD risk (1). The Collabo-
ration’s million-person database also demonstrated
that, independent of BP, increasing age is a powerful
determinant of events. It could unwisely be argued
that absolute event rates in young people, even when
increased by high BP, remain relatively low. In fact,the growing prevalence of hypertension, along with
obesity, lipid disorders, and diabetes, in young peo-
ple has become a major public health issue. Indeed, it
is to be hoped that early management of hypertension
in young adults might beneﬁcially alter its natural
history and reduce the incidence of cardiovascular
events in later life.
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